Sartorius Stedim stock holds steady as ADR trades at mid-August level
Published on 08/17/2026 at 14:40 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Sartorius Stedim Biotech SA (FR0013154002) is trading at a mid-August level on its U.S. ADR, with the SRTOY line last closing at $20.66 on August 14, 2026 as investors reassess bioprocessing valuations.
ADR pricing and market context
The latest available quote for the Sartorius Stedim ADR shows a price of $20.66, with a decline of 1.68% on August 14, 2026 and trading volume of 74,462 shares according to a recent market-data overview market data overview for SRTOY ADR. The move represented a drop of $0.35 from the prior session, underlining how sensitive biopharma suppliers remain to sentiment changes comparative chart for SRTOY ADR.
On the European side, the broader Sartorius group is quoted at EUR190.00 per share for the Sartorius Aktiengesellschaft line as of August 14, 2026, highlighting the different absolute price levels between the home-market listing and the U.S. ADR quote overview for Sartorius Aktiengesellschaft. For investors looking at both instruments, the ADR price of $20.66 versus the EUR190.00 home-market price underlines the importance of understanding the ADR ratio and currency effects when comparing valuations.
Fundamentals and investor lens
The recent ADR performance, with a 1.68% decline to $20.66 on August 14, 2026, invites a closer look at how Sartorius Stedim fundamentals support its valuation SRTOY ADR performance snapshot. While specific revenue and earnings figures for the most recent quarter are not highlighted in the available same-day sources, the bioprocessing specialist is generally viewed through metrics such as growth in single-use technologies, margin resilience, and exposure to biologics and cell and gene therapy manufacturing.
In valuation terms, investors often compare Sartorius Stedim against a peer basket of European pharma and biotech names that are tracked in dedicated overviews of French pharmaceuticals and biotech stocks overview of French pharma and biotech stocks. In that context, the ADR move to $20.66 and the home-market price of EUR190.00 as of mid-August 2026 encourage investors to balance growth expectations in bioprocessing with broader sector performance.
Bioprocessing solutions and product focus
Sartorius Stedim Biotech SA focuses on equipment and consumables used in the development and manufacture of biopharmaceuticals, including single-use bioreactors, filtration systems, and analytical tools. These products support upstream and downstream processing steps in biologics production, where reliability and scalability are essential for drug developers and contract manufacturers. The company’s solutions are designed to help customers move therapies from clinical development into commercial-scale manufacturing while meeting stringent regulatory standards.
Sartorius Stedim stock and mid-August pricing
With the Sartorius Stedim ADR last quoted at $20.66 as of August 14, 2026, and the Sartorius Aktiengesellschaft home-market share at EUR190.00 on the same date, the stock reflects a stable mid-August level that anchors investor discussions around fundamentals and growth in bioprocessing.
Fact box
Company: Sartorius Stedim Biotech SA
ISIN: FR0013154002
Ticker: SRTOY (ADR); SRT (home-market group line)
Exchange: OTC (ADR); Frankfurt/Euronext-style European listing for the group
Price (as of August 14, 2026, 3:59 p.m. ET for ADR): $20.66 USD
Market cap: not specified in the available same-day data
Sector / Industry: Pharmaceuticals / Biotech equipment and bioprocessing
Index membership: included in French pharma and biotech stock overviews
